Abstract
The USA pays more for brand-name prescription drugs than any other country and new legislation from August 2022 gives Medicare the authority to directly negotiate certain drug prices with manufacturers starting in 2026—something the federal insurer had been prohibited from doing for its prior history. As the USA prepares for negotiations, we therefore surveyed how comparable industrialized countries use statutory requirements and procedures to negotiate brand-name drug prices. Guidance documents, regulations, government and academic publications were reviewed to identify the process of negotiating drug prices in peer countries that have been cited as potential examples for US payment reform: Australia, Canada, France, Germany, and the UK. Processes for arriving at a final price for a drug generally fall under three approaches: statutory rebates, setting a maximum price, and arbitration between national (public) insurers and manufacturers. Each approach to price negotiation could be adopted by Medicare and reduce spending even if Medicare does not adopt an exclusionary or closed formulary. Much remains to be determined about how the new price negotiation authority in the USA will be implemented, and policymakers can learn from comparator countries’ statutory and regulatory strategies for price negotiation.
Similar content being viewed by others
References
Medicare Prescription Drug, Improvement, and Modernization Act of 2003. 108th Congress ed 2003.
LaRosa J, Slifer E. Key provisions of drug pricing proposals. Commonwealth Fund, New York, NY. https://www.commonwealthfund.org/publications/2021/apr/key-provisions-drugpricing-proposals. Accessed 26 May 2021
Inflation Reduction Act of 2022. 117th Congress ed 2022.
Werble C. Medicare Part B. Health Affairs Blog: Project Hope; 2017. https://www.healthaffairs.org/do/10.1377/hpb20171008.000171/full. Accessed 22 September 2021
Sachs R. Understanding the Democrats drug pricing package. Health Affairs Forefront: Project Hope; 2022.
Kelly C, Karlin-Smith S. Medicare price 'negotiation' process gets broad brush treatment in new law. Scrip. 16 Aug 2022.
H.R.3 - Elijah E. Cummings lower drug costs now act. 116th Congress ed: Congress.gov; 2019.
Rand LZ, Kesselheim AS. International reference pricing for prescription drugs: a landscape analysis. J Manage Care Spec Pharm. 2021;27(9):1309–13.
Emanuel EJ, Zhang C, Glickman A, Gudbranson E, DiMagno SSP, Urwin JW. Drug reimbursement regulation in 6 peer countries. JAMA Intern Med. 2020;180(11):1510–7. https://doi.org/10.1001/jamainternmed.2020.4793
Kristensen FB. Mapping of HTA methodologies in EU and Norway. Corporate author: European Commission, Directorate-General for Health and Food Safety, Publications Office, Brussels; 2017. https://op.europa.eu/en/publication-detail/-/publication/4d364ea4-113a-11e8-9253-01aa75ed71a1
Rand LZ, Kesselheim AS. An international review of health technology assessment approaches to prescription drugs and their ethical principles. J Law Med Ethics. 2020;48(3):583–94.
Rodwin MA. Common pharmaceutical price and cost controls in the United Kingdom, France, and Germany: lessons for the United States. Int J Health Serv. 2021;51(3):379–91.
Wenzl M, Paris V. Pharmaceutical Reimbursement and Pricing in Germany. OECD. Paris. June 2018. https://www.oecd.org/health/health-systems/Pharmaceutical-Reimbursement-and-Pricing-in-Germany.pdf. Accessed 6 May 2021
The benefit assessment of medicinal products in accordance with the German Social Code, Book Five (SGB V), section 35a. https://www.g-ba.de/english/benefitassessment/. Accessed 21 Oct 2019.
GKV-Spitzenverband. Digitalisation in the healthcare system: annual report 2019. GKV-Spitzenverband, Berlin; 2020. https://www.gkv-spitzenverband.de/media/dokumente/service_1/publikationen/geschaeftsberichte/GKV_GB2019_englisch_Barrierefrei.pdf. Accessed 2 Aug 2022.
Ludwig S, Dintsios CM. Arbitration board setting reimbursement amounts for pharmaceutical innovations in Germany when price negations between payers and manufacturers fail: an empirical analysis of 5 years’ experience. Value Health. 2016;19(8):1016–25.
Rother J. Is arbitration an answer for high drug prices? To the Point: Commonwealth Fund; GKV-Spitzenverband. https://www.gkvspitzenverband.de/media/dokumente/service_1/publikationen/geschaeftsberichte/GKV_GB2019_englisch_Barrierefrei.pdf 2019.
Robinson JC. Lower prices and greater patient access: lessons from Germany’s drug-purchasing structure. N Engl J Med. 2020;382(23):2177–9.
Moorkens E, Barcina Lacosta T, Vulto AG, Schulz M, Gradl G, Enners S, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany. Pharmaceuticals (Basel). 2020;13(10):324.
Lauenroth VD, Stargardt T. Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? Value Health. 2017;20(7):927–35.
Gandjour A, Schussler S, Hammerschmidt T, Dintsios CM. Predictors of negotiated prices for new drugs in Germany. Eur J Health Econ. 2020;21(7):1049–57.
Jantschak F. Pricing and reimbursement decisions in Germany. Access to innovative oncology drugs in Europe. Berlin, Madrid; 2017.
Staab TR, Walter M, Mariotti Nesurini S, Dintsios CM, Graf von der Schulenburg JM, Amelung VE, et al. “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ Rev. 2018;8(1):23.
Isabelle DZ. International Health Care System Profiles: France. The Commonwealth Fund. New York, NY. 2020. https://www.commonwealthfund.org/international-health-policy-center/countries/france. Accessed 25 August 2021.
Haute Autorité de Santé. Pricing & reimbursement of drugs and HTA policies in France. 2015. https://www.has-sante.fr/jcms/c_1729421/en/transparency-committee. Accessed 17 Mar 2021.
Raimond V, Feldman WB, Rome BN, Kesselheim AS. Why France spends less than the United States on drugs: a comparative study of drug pricing and pricing regulation. Milbank Q. 2021;99(1):240–72.
Nouguez Et, Benoît C. Governing (through) prices: the State and pharmaceutical pricing in France. Rev Fr Sociol. 2017;58(3):399–424.
Comité économique des produits de santé and LEEM. Accord-cadre du 05/03/2021 entre le Comité économique des produits de santé et les entreprises du médicament (Leem). Ministère des solidarités et de la santé. 5 March 2021. https://solidarites-sante.gouv.fr/IMG/pdf/accord_cadre_21-24_signe.pdf. Accessed 17 May 2021
Dumitrescu R, Cahuzac C. New "Accord Cadre" finally released by the CEPS in France. 13 July 2021. https://www.simon-kucher.com/en-us/blog/new-accord-cadre-finally-released-ceps-france. Accessed 26 Aug 2021.
Comité économique des produits de santé and LEEM. Accord-cadre du 05/03/2021 entre le Comité économique des produits de santé et les entreprises du médicament (Leem). Ministère des solidarités et de la santé. 5 March 2021. https://solidarites-sante.gouv.fr/IMG/pdf/accord_cadre_21-24_signe.pdf. Accessed 17 May 2021
Leem. Economic regulation of medicines: Leem and CEPS (the French Economic Committee for Health Prodcuts) sign a new threeyear framework agreement (2021-2024). Les Entreprises du Médicament; Paris, 2021. https://www.leem.org/sites/default/files/2021-03/Communiqué%20de%20presse%20version%20anglaise%20accord-cadre.pdf. Accessed 17 May 2021
Rodwin MA. Pharmaceutical price and spending controls in France: lessons for the United States. Int J Health Serv. 2020;50(2):156–65.
Pharmaceutical Benefits Scheme. Fact sheet: setting an approved ex-manufacturer price for new or extended listings. 25 July 2017. Paris. Online press release https://www.leem.org/sites/default/files/2021-03/Communiqu%C3%A9%20de%20presse%20version%20anglaise%20accord-cadre.pdf. Accessed 17 May 2021
PBS. Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme. ed. 2.0. updated 11 May 2022 Australian Government, Department of Health. https://www.pbs.gov.au/pbs/industry/listing/listing-steps. Accessed 3 August 2022
Services Australia. PBS for pharmacists. 1 July 2022. https://www.servicesaustralia.gov.au/about-pbs-for-pharmacists?context=22861/. Accessed 3 Aug 2022.
Mulcahy AW, Whaley C, Tebeka MG, Schwam D, Edenfield N, Becerra-Ornelas AU. International prescription drug price comparisons. RAND Corporation, Santa Monica, CA; 2021. https://www.rand.org/pubs/research_reports/RR2956.html. Accessed 16 December 2021
Williams G, Rose A. Reimbursement of medicines in Australia: maximising opportunities in an increasingly challenging environment. Practical law. Thomson Reuters; 2016.
Department of Health and Social Care, ABPI. The 2019 voluntary scheme for branded medicines pricing and access: chapters and glossary. In: Care HaS, editor. gov.uk: Department of Health and Social Care; Crown; RAND Corporation, Santa Monica, CA https://www.rand.org/pubs/research_reports/RR2956.html 2019.
Community Care/Medicines and Pharmacy/Medicines Pricing and Supply/Cost Centre No. 17080. The 2019 voluntary scheme for branded medicines pricing and access - Annexes 2018. Eagan, MN. Online resource on law. https://content.next.westlaw.com/4-627-2988?__lrTS=20200901092320075&transitionType=Default&contextData=(sc.Default)&firstPage=true. Accessed 16 December 2021
Department of Health and Social Care. Statutory scheme to control costs of branded health service medicines. 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/859212/statutory-scheme-to-control-costs-of-branded-medicines-impact-assessment.pdf. Accessed 15 April 2021
Rodwin MA. How the United Kingdom controls pharmaceutical prices and spending: learning from its experience. Int J Health Serv. 2021;51(2):229–37.
Rodriguez Santana I, Aragon MJ, Rice N, Mason AR. Trends in and drivers of healthcare expenditure in the English NHS: a retrospective analysis. Health Econ Rev. 2020;10(1):20. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/859212/statutory-10.1007/s40273-022-01195-xscheme-to-control-costs-of-branded-medicines-impact-assessment.pdf. Accessed 15 April 2021.
Wang S, Gum D, Merlin T. Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC: does the presence of an explicit threshold affect the ICER proposed? Value Health. 2018;21(8):938–43.
MacPhail E, Shea B. An inside look at the early history of the CADTH common drug review in Canada. 2017.
PMPRB draft guidelines. 2020.
pCPA. About pCPA. 2021. https://www.pcpacanada.ca/about. Accessed 7 Apr 2021.
pCPA. The negotiation process. 2021. https://www.pcpacanada.ca/negotiation-process. Accessed 7 Apr 2021.
Standing Committee on Health, Casey (chair) B. Pharmacare now: prescription medicine coverage for all Canadians. 42nd Parliament, 1st Session 2018.
The drug review process in B.C. Detailed. 2020. https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/drugrevproc.pdf. Accessed 8 Apr 2021.
pan-Canadian Pharmaceutical Alliance. pCPA Brand Process Guidelines. rev. April 2019. pCPA Office, Toronto. https://www.pcpacanada.ca/sites/default/files/aoda/pCPA_Brand_Process_Guidelines_EN_FINAL-s.pdf. Accessed 7 April 2021
Morgan, S. We need innovation in our drug price regulations. 30 May 2019. In Policy Options. IRPP, Montreal. https://policyoptions.irpp.org/magazines/may-2019/we-need-innovation-in-our-drug-price-regulations/. Accessed 19 May 2021
Regulations amending the regulations amending the Patented Medicines Regulations (additional factors and information reporting requirements), No. 5: SOR/2022-162. Canada Gazette. 24 Jun 2022.
An Act to enact the Canada Pharmacare Act. 43rd Parliament, 2nd Session ed. 2021.
Lexchin J. After more than 50 years, Pharmacare (and Dental Care) are coming to Canada. Int J Health Serv. 2022;52(3):341–6.
Committee on Oversight and Reform. Drug pricing investigation: AbbVie: Humira and Imbruvica. Staff report. Washington DC; 2021.
Administrative Dispute Resolution Act of 1996. 104th Congress ed.
IQWiG. Fingolimod:benefit assessment according to §35a Social Code Book V. Cologne. 29 Jun 2015.
HAS. Gilenya (fingolimod). 18 May 2018.
PBAC. Public summary document: fingolimod, capsule, 0.5 mg (as hydrochloride), Gilenya®, 1 Jul 2011.
NICE. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. 25 Apr 2012.
Canadian Drug Expert Committee. CDEC final recommendation: fingolimod. 16 Nov 2011.
Virji S. New analyses convince IQWiG that Novartis's MS drug is better than previously thought. Scrip. 7 Jul 2015.
Transparence Cdl. Avis: Gilenya 2011; 20 Jul.
pCPA. Gilenya (fingolimod). https://www.pcpacanada.ca/negotiation/20787. Accessed 3 Aug 2022.
Patented medicines for human use reported to the PMPRB in 2020*. 31 March 2022. https://www.canada.ca/en/patented-medicine-prices-review/services/annual-reports/patented-medicines-reported-2020.html#listn. Accessed 2 Aug 2022.
Lauer-Taxe. CGM Lauer; 2022.
Bruce F. Intermune's 'minor improvement' ges $25k-a-year price in France. Scrip. 12 Sep 2012.
Hussein S. 'My' MS, a magic pill, and what the PBS fight means to me. Crikey. 29 Apr 2011.
Gilenya (Fingolimod). 2022. https://www.canadapharmacyonline.com/DrugInfo.aspx?name=Gilenya6772. Accessed 2 Aug 2022.
First Databank. AnalySource; 2022.
Red Book. IBM Micromedex; 2022.
PBS. Fingolimod, general schedule. 2022. https://www.pbs.gov.au/medicine/item/5262Y. Accessed 19 May 2021.
Ontario Drug Benefit Formulary/Comparative Drug Index: Gilenya. 17 December 2021; version 2.12. Available from: https://www.formulary.health.gov.on.ca/formulary/results.xhtml?q=gilenya&type=2. Accessed 2 Aug 2022.
Centers for Medicare and Medicaid Services. Medicare Part D spending by drug. 2020. Available from: https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug. Accessed 3 Aug 2022
Office of the Auditor General of Ontario. Annual Report 2017. vol 1. 2017. Queen's Printer for Ontario, Ontario. https://www.auditor.on.ca/en/content/annualreports/arreports/en17/2017AR_v1_en_web.pdf. Accessed 4 August 2022
Acknowledgments
The authors thank Huseyin Naci, Veronique Raimond, Edward R. Cliff, Kerstin N. Vokinger, and Matthew Herder for feedback on the article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Arnold Ventures provided funding for the preparation of this article.
Conflicts of interest/Competing interests
Leah Z. Rand and Aaron S. Kesselheim have no conflicts of interest that are directly relevant to the content of this article.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Authors’ contributions
Both authors contributed to the study conception and design. Data collection and analysis were performed by LZR. The first draft of the manuscript was written by LZR, ASK commented on and revised the manuscript. Both authors read and approved the final manuscript.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rand, L.Z., Kesselheim, A.S. Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries. PharmacoEconomics 40, 1131–1142 (2022). https://doi.org/10.1007/s40273-022-01195-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-022-01195-x